A Series B venture capital financing round worth £15 million has been led by Fidelity Biosciences and Novo A/S.
Molecular diagnostics business Biofortuna has closed another round of venture capital funding so that it can target the US market.
The steady income streams and low risk profiles of pharmacy businesses are proving increasingly attractive for private equity investors, new figures suggest.
An eight-year involvement with dental membership plan business Practice Plan has netted Dunedin Private Equity a 2.8x return on its investment.
Science in Sport is targeting its share of a reported £19.6 billion global market in 2010 by securing a stock market listing.
Private equity firm Graphite Capital has followed up on its recent investment in the Hawksmoor chain of restaurants by exiting its interest in Willowbrook Healthcare.
The Biomedical Catalyst is allocating £25.9 million as part of a new support package for businesses and academic projects in the health industry.
The Seed Enterprise Investment Scheme (SEIS) has allowed biotechnology business Oxford Genetics to net £150,000 of new funding.
The North West Fund for Biomedical and Fusion IP are coming together to back the growth ambition of University of Sheffield spin-out Absynth Biologics.
A £250,000 investment led North West Fund for Biomedical will be used by Tomorrows Medicines to commercialise its new platform.
Private equity firm ECI Partners has sold its stake in CliniSys and netted a 2.5x return on its 2007 investment.
Venture capital firm Atomico has stepped up to lead a $10 million investment into ChemistDirect.
AIM-listed investment firm Imperial Innovations Group has secured a £30 million loan so that it can make investments in the biotech and therapeutics sectors.
A thirty one-year old specialist furniture business has taken on private equity backing as it looks to grow through organic and acquisitive means.
The £25 million North West Fund for Biomedical has made its 57th investment to date through the backing of Perfectus Biomed.
An $11 million investment from Index Ventures will be used to develop an anticoagulant drug aimed at preventing heart attacks and strokes without causing bleeding.
Growth Capital Partners portfolio company Fishawack has completed its first acquisition since the private equity firm backed a secondary buy-out at the company back in March.
A new collaboration between Alliance Boots and BioCity will see the creation of a new business incubator focused on health and wellness.
Octopus Investments has led a £2 million investment into clinical trials platform TrialReach alongside Amadeus Capital Partners.
Cerus Endovascular is moving its operations to Liverpool Science Park following backing from The North West Fund for Biomedical.
Jamie Turner, CTO at Postcode Anywhere, examines Tech Entrepreneur Week to determine what must be done to build a great technology company.
For investors looking for good returns, picking what type of alternative finance to engage with is an important decision.
Taking Tech Invest north in search of businesses hoping to grow through equity funding.
Research report into the top-performing 100 companies below the FTSE 350 and on AIM.